Alzchem Group H1 EBITDA up 14.8 pct at 27.9 million euros - Reuters
| ACT Stock | EUR 57.80 0.40 0.70% |
Slightly above 51% of AlzChem Group's private investors are presently thinking to get in. The analysis of current outlook of investing in AlzChem Group AG suggests that some traders are interested regarding AlzChem Group's prospects. AlzChem Group's investing sentiment can be driven by a variety of factors including economic data, AlzChem Group's earnings reports, geopolitical events, and overall market trends.
AlzChem |
Alzchem Group H1 EBITDA up 14.8 pct at 27.9 million euros Reuters
Read at news.google.com
 |
AlzChem Group Fundamental Analysis
We analyze AlzChem Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AlzChem Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AlzChem Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
AlzChem Group is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
AlzChem Group AG Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with AlzChem Group stock to make a market-neutral strategy. Peer analysis of AlzChem Group could also be used in its relative valuation, which is a method of valuing AlzChem Group by comparing valuation metrics with similar companies.
Peers
AlzChem Group Related Equities
| 6B0 | SOFI TECHNOLOGIES | 3.54 | ||||
| 762 | PKSHA TECHNOLOGY | 0.81 | ||||
| PL8 | Playtech Plc | 0.11 | ||||
| HNM | ORMAT TECHNOLOGIES | 0.81 | ||||
| MZZ1 | Digilife Technologies | 1.32 | ||||
| KM3 | KENNAMETAL INC | 1.56 | ||||
| 1D8 | ACCSYS TECHPLC | 1.85 |
Additional Tools for AlzChem Stock Analysis
When running AlzChem Group's price analysis, check to measure AlzChem Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AlzChem Group is operating at the current time. Most of AlzChem Group's value examination focuses on studying past and present price action to predict the probability of AlzChem Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AlzChem Group's price. Additionally, you may evaluate how the addition of AlzChem Group to your portfolios can decrease your overall portfolio volatility.